Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2017

View Archived Issues

CFFT award supports Aridis' development of Panaecin for patients with cystic fibrosis

AMAG Pharmaceuticals enters licensing agreement with Palatin Technologies for bremelanotide

Aduro Biotech, Merck & Co. to investigate CRS-207 plus pembrolizumab in gastric cancer

ProNAi Therapeutics changes name to Sierra Oncology, transfers phase I trials of SRA-737

Phase I trial begins for Moderna's mRNA-based Zika vaccine candidate

DSMB recommends continuation of Evgen's phase II trial of SFX-01 in subarachnoid hemorrhage

IACTA acquires North American rights to Nanomerics' NM-133 for dry eye

Gemcabene shows efficacy for NASH in preclinical proof-of-concept study

LegoChem and Takeda enter research licensing agreement to evaluate next-generation ADC candidates

Abivax to receive funding to strengthen antiviral platform

G1 Therapeutics begins three breast cancer drug programs

Gilead's Vemlidy approved for HBV infection in E.U.

FDA grants orphan drug status to Sangamo Therapeutics' SB-318

Targeted knockdown of SMN-AS1 as a potential new SMA therapeutic strategy

FDA issues complete response letter for Tesaro's NDA for intravenous rolapitant

Genomics-based drug repurposing identifies sitagliptin as potential antiepileptic drug

FDA grants QIDP and fast track designations to VivaGel in bacterial vaginosis

RedHill Biopharma's RHB-104 awarded FDA QIDP designation

Gas6-AXL pathway as a new target for development of ZIKV therapies

Bird Rock Bio cleared to begin phase I study of namacizumab

Bayer patents anticancer compounds

Takeda reports M1 PAMs for Alzheimer's disease

Kissei Pharmaceutical describes TRPM8 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...